- Home
- RCKT vs ORGO Comparison
RCKT vs ORGO Comparison
Compare RCKT & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- ORGO
- Stock Information
- Founded
- RCKT 1999
- ORGO 1985
- Country
- RCKT United States
- ORGO United States
- Employees
- RCKT N/A
- ORGO N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- RCKT Health Care
- ORGO Health Care
- Exchange
- RCKT Nasdaq
- ORGO Nasdaq
- Market Cap
- RCKT 326.4M
- ORGO 384.4M
- IPO Year
- RCKT N/A
- ORGO N/A
- Fundamental
- Price
- RCKT $2.70
- ORGO $3.25
- Analyst Decision
- RCKT Buy
- ORGO Buy
- Analyst Count
- RCKT 13
- ORGO 2
- Target Price
- RCKT $18.50
- ORGO $5.50
- AVG Volume (30 Days)
- RCKT 8.4M
- ORGO 911.8K
- Earning Date
- RCKT 08-04-2025
- ORGO 08-07-2025
- Dividend Yield
- RCKT N/A
- ORGO N/A
- EPS Growth
- RCKT N/A
- ORGO N/A
- EPS
- RCKT N/A
- ORGO N/A
- Revenue
- RCKT N/A
- ORGO $458,760,000.00
- Revenue This Year
- RCKT N/A
- ORGO $2.62
- Revenue Next Year
- RCKT N/A
- ORGO $12.46
- P/E Ratio
- RCKT N/A
- ORGO N/A
- Revenue Growth
- RCKT N/A
- ORGO 5.35
- 52 Week Low
- RCKT $2.19
- ORGO $2.28
- 52 Week High
- RCKT $26.98
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- RCKT 32.09
- ORGO 48.02
- Support Level
- RCKT $2.66
- ORGO $3.08
- Resistance Level
- RCKT $3.33
- ORGO $3.71
- Average True Range (ATR)
- RCKT 0.28
- ORGO 0.21
- MACD
- RCKT 0.09
- ORGO 0.07
- Stochastic Oscillator
- RCKT 26.59
- ORGO 55.45
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.